Table 2. Clinical features with MYC, BCL2 and double CNA.
| Characteristics | MYC CNA+ | MYC CNA− | P value | BCL2 CNA+ | BCL2 CNA− | P value | MC+BC+ | MC−BC− | P value |
|---|---|---|---|---|---|---|---|---|---|
| No. of cases (%) | No. of cases (%) | No. of cases (%) | |||||||
| Age (years) | 18 | 222 | 65 | 175 | 9 | 166 | |||
| ≤ 60 | 7 (38.9) | 139 (62.6) | 0.047 | 30 (46.2) | 116 (66.3) | 0.005 | 2 (22.2) | 111 (66.9) | 0.010 |
| > 60 | 11 (61.1) | 83 (37.3) | 35 (53.8) | 59 (33.7) | 7 (77.8) | 55 (33.1) | |||
| Sex | 18 | 222 | 65 | 175 | 9 | 166 | |||
| Male | 14 (77.8) | 134 (60.4) | 0.144 | 46 (70.8) | 102 (58.3) | 0.077 | 6 (66.7) | 94 (56.6) | 0.734 |
| Female | 4 (22.2) | 88 (39.6) | 19 (29.2) | 73 (41.7) | 3 (33.3) | 72 (43.4) | |||
| Stage | 18 | 213 | 63 | 168 | 9 | 159 | |||
| III–IV | 12 (66.7) | 110 (51.6) | 0.220 | 30 (47.6) | 92 (54.8) | 0.333 | 4 (44.4) | 84 (52.8) | 0.738 |
| I–II | 6 (33.3) | 103 (48.4) | 33 (52.4) | 76 (45.2) | 5 (55.6) | 75 (47.2) | |||
| LDH | 18 | 213 | 63 | 168 | 9 | 159 | |||
| Elevated | 9 (50.0) | 90 (42.3) | 0.524 | 32 (50.8) | 67 (39.9) | 0.136 | 4 (44.4) | 62 (39.0) | 0.739 |
| Normal | 9 (50.0) | 123 (57.7) | 31 (49.2) | 101 (60.1) | 5 (55.6) | 97 (61.0) | |||
| ECOG PS | 18 | 222 | 65 | 175 | 9 | 166 | |||
| ≥ 2 | 4 (22.2) | 36 (16.2) | 0.512 | 17 (26.2) | 23 (13.1) | 0.016 | 2 (22.2) | 21 (12.7) | 0.336 |
| < 2 | 14 (77.8) | 186 (83.8) | 48 (73.8) | 152 (86.9) | 7 (77.8) | 145 (87.3) | |||
| Extranodal involvement | 18 | 213 | 63 | 170 | 9 | 159 | |||
| ≥ 2 | 4 (22.2) | 44 (20.7) | 0.772 | 15 (23.8) | 35 (25.6) | 0.595 | 2 (22.2) | 31 (19.5) | 1.000 |
| < 2 | 14 (77.8) | 169 (79.3) | 48 (76.2) | 135 (79.4) | 7 (77.8) | 128 (80.5) | |||
| IPI | 18 | 213 | 63 | 168 | 9 | 159 | |||
| 3–5 | 9 (50.0) | 53 (24.9) | 0.028 | 19 (30.2) | 43 (22.6) | 0.486 | 4 (44.4) | 38 (23.9) | 0.230 |
| 0–2 | 9 (50.0) | 160 (75.1) | 44 (69.8) | 125 (74.4) | 5 (55.6) | 121 (76.1) | |||
| B symptoms | 18 | 222 | 65 | 175 | 9 | 166 | |||
| Positive | 5 (27.8) | 79 (35.6) | 0.504 | 27 (41.5) | 57 (32.6) | 0.196 | 3 (33.3) | 55 (33.1) | 1.000 |
| Negative | 13 (72.2) | 143 (64.4) | 38 (58.5) | 118 (67.4) | 6 (66.7) | 111 (66.9) | |||
| COO (Hans) | 18 | 222 | 65 | 175 | 9 | 166 | |||
| GCB | 5 (27.8) | 93 (41.9) | 0.241 | 17 (26.2) | 81 (46.3) | 0.005 | 2 (22.2) | 78 (47.0) | 0.183 |
| Non-GCB | 13 (72.2) | 129 (58.0) | 48 (73.8) | 94 (53.7) | 7 (77.8) | 88 (53.0) | |||
Abbreviations: CNA: copy number aberration; MC+BC+: MYC CNA concurrent with BCL2 CNA; MC−BC−: negative for both MYC CNA and BCL2 CNA; COO: cell of origin; ECOG PS: performance status of Eastern Cooperative Oncology Group; GCB: germinal-center B-cell type; IPI: International Prognostic Index; LDH: lactate dehydrogenase.